Antithrombotic Treatment of Embolic Stroke of Undetermined Source
Open Access
- 1 June 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 51 (6), 1758-1765
- https://doi.org/10.1161/strokeaha.119.028643
Abstract
Background and Purpose— The RE-SPECT ESUS trial (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) tested the hypothesis that dabigatran would be superior to aspirin for the prevention of recurrent stroke in patients with embolic stroke of undetermined source. This exploratory subgroup analysis investigates the impact of age, renal function (both predefined), and dabigatran dose (post hoc) on the rates of recurrent stroke and major bleeding. Methods— RE-SPECT ESUS was a multicenter, randomized, double-blind trial of dabigatran 150 or 110 mg (for patients aged ≥75 years and/or with creatinine clearance 30 to P=0.01). This was driven mainly by the subgroup aged ≥75 years (7.8% versus 12.4%; hazard ratio, 0.63 [95% CI, 0.43–0.94]; interaction P=0.10). Stroke rates tended to be lower with dabigatran versus aspirin with declining renal function. Risks for major bleeding were similar between treatments, irrespective of renal function, but with a trend for lower bleeding rates with dabigatran versus aspirin in older patients. Conclusions— In subgroup analyses of RE-SPECT ESUS, dabigatran reduced the rate of recurrent stroke compared with aspirin in patients qualifying for the lower dose of dabigatran. These results are hypothesis-generating. Aspirin remains the standard antithrombotic treatment for patients with embolic stroke of undetermined source. Registration—URL: https://www.clinicaltrials.gov; Unique identifier: NCT02239120.This publication has 19 references indexed in Scilit:
- Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined SourceThe New England Journal of Medicine, 2019
- Design of Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate vs. Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source (Re-Spect Esus)International Journal of Stroke, 2015
- Cryptogenic strokeEuropean Journal of Neurology, 2015
- Embolic Strokes of Undetermined Source in the Athens Stroke RegistryStroke, 2015
- Embolic strokes of undetermined source: the case for a new clinical constructThe Lancet Neurology, 2014
- Subclinical Atrial Fibrillation and the Risk of StrokeThe New England Journal of Medicine, 2012
- Independent predictors of stroke in patients with atrial fibrillationNeurology, 2007
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Infarcts of undetermined cause: The NINCDS stroke data bankAnnals of Neurology, 1989